Key result
Regular lipoprotein apheresis over 4.5 years successfully stabilized progressive ischemic events and induced impressive neurologic and physical rehabilitation in a patient with severe Lipoprotein(a)-hyperlipoproteinemia and chronic spinal cord ischemia.
Why the study?
Does lipoprotein apheresis improve clinical outcomes and neurologic deficits in a patient with progressive Lp(a)-associated ischemic syndromes?
Case Report (n=1)
No
Does lipoprotein apheresis improve clinical outcomes and neurologic deficits in a patient with progressive Lp(a)-associated ischemic syndromes?
Lipoprotein apheresis may be a viable treatment option to halt and reverse progressive ischemic syndromes, including vascular myelopathy, in patients with severe Lp(a)-hyperlipoproteinemia.
Answers are grounded in this paper and cite their sources.
May support apheresis in refractory Lp(a)-myelopathy; hypothesis-generating and requires prospective confirmation.
High concentrations of lipoprotein(a) (Lp(a)) represent an important independent and causal risk factor associated with adverse outcome in atherosclerotic cardiovascular disease (CVD). Effective Lp(a) lowering drug treatment is not available. Lipoprotein apheresis (LA) has been proven to prevent cardiovascular events in patients with Lp(a)-hyperlipoproteinemia (Lp(a)-HLP) and progressive CVD. Here we present the course of a male patient with established peripheral arterial occlusive disease (PAOD) at the early age of 41 and coronary artery disease (CAD), who during follow-up developed over 2 years a progressive syndrome of cerebellar and spinal cord deficits against the background of multifactorial cardiovascular risk including positive family history of CVD. Spastic tetraplegia and dependency on wheel chair and nursing care represented the nadir of neurological deficits. All conventional risk factors including LDL-cholesterol had already been treated and after exclusion of other causes, genetically determined Lp(a)-HLP was considered as the major underlying etiologic factor of ischemic vascular disease in this patient including spinal cord ischemia with vascular myelopathy. Treatment with an intensive regimen of chronic LA over 4.5 years now was successful to stabilize PAOD and CAD and led to very impressive neurologic and overall physical rehabilitation and improvement of quality of life.Measurement of Lp(a) concentration must be recommended to assess individual cardiovascular risk. Extracorporeal clearance of Lp(a) by LA should be considered as treatment option for select patients with progressive Lp(a)-associated ischemic syndromes.
No takes yet. Share an insight, caveat, or question.
Heigl et al. (2017) conducted a case report in Lipoprotein(a)-hyperlipoproteinemia and chronic spinal cord ischemia (n=1). Lipoprotein apheresis was evaluated on Neurological and physical rehabilitation. Regular lipoprotein apheresis over 4.5 years successfully stabilized progressive ischemic events and induced impressive neurologic and physical rehabilitation in a patient with severe Lipoprotein(a)-hyperlipoproteinemia and chronic spinal cord ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: